<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499174</url>
  </required_header>
  <id_info>
    <org_study_id>PR11</org_study_id>
    <secondary_id>U10CA077202</secondary_id>
    <secondary_id>CAN-NCIC-CTG-PR11</secondary_id>
    <secondary_id>CALGB-140602</secondary_id>
    <secondary_id>SWOG-PR11</secondary_id>
    <secondary_id>CDR0000557348</secondary_id>
    <secondary_id>RTOG-0873</secondary_id>
    <secondary_id>ECOG-JPR.11</secondary_id>
    <secondary_id>ICR-CTSU-ProSTART</secondary_id>
    <nct_id>NCT00499174</nct_id>
  </id_info>
  <brief_title>Observation or Radical Treatment in Patients With Prostate Cancer</brief_title>
  <official_title>A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed With Favourable Risk Prostate Cancer [START]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sometimes prostate tumours may not need treatment until they progress. In this&#xD;
      case, observation may be sufficient. Radical treatments, such as radical prostatectomy or&#xD;
      radiation therapy, may be effective in treating prostate cancer when it is first diagnosed.&#xD;
      It is not yet known whether active surveillance is more effective than radical treatment as&#xD;
      an initial intervention in favorable prognosis prostate cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying active surveillance to see how well it&#xD;
      works compared with radical treatment as an initial intervention in patients with favorable&#xD;
      prognosis prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare disease-specific survival of patients with favorable risk prostate cancer&#xD;
           treated with radical prostatectomy or radical radiotherapy at the time of initial&#xD;
           diagnosis vs active surveillance and selective intervention based on pre-specified&#xD;
           biochemical, histological, or clinical progression criteria.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare overall survival, quality of life using the EPIC-26, RAND SF-12, and&#xD;
           State-Trait Anxiety Inventory, distant disease-free survival, PSA relapse/progression&#xD;
           after radical intervention, and initiation of androgen deprivation therapy between the&#xD;
           two treatment arms.&#xD;
&#xD;
        -  To determine the proportion of patients on the active surveillance arm who receive&#xD;
           radical intervention for prostate cancer.&#xD;
&#xD;
        -  To determine if PSA doubling-time prior to diagnosis predicts eventual outcome.&#xD;
&#xD;
        -  To determine if molecular biomarkers predict outcome.&#xD;
&#xD;
      OUTLINE: This is a prospective, randomized, multicenter study. Patients are stratified by&#xD;
      treatment center, ECOG performance status (0 vs 1 or 2), disease stage (T1 vs T2), baseline&#xD;
      PSA value (ng/mL or μg/L) (&lt; 5.0 vs ≥ 5.0 and ≤ 10.0), and age (&lt; 65 years vs ≥ 65 years).&#xD;
      Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
        -  Arm I: Patients undergo radical intervention (radical prostatectomy or radiotherapy&#xD;
           [external-beam radiotherapy 5 days a week for 4-8 weeks; permanent prostate&#xD;
           brachytherapy; or high-dose rate temporary brachytherapy], based on patient and&#xD;
           physician preference).&#xD;
&#xD;
        -  Arm II: Patients undergo active surveillance with radical intervention at the time one&#xD;
           or more pre-specified criteria (biochemical progression, histologic/grade progression,&#xD;
           and/or clinical progression) are met.&#xD;
&#xD;
      Quality of life is assessed by the EPIC-26, RAND SF-12, and State Anxiety Inventory at&#xD;
      baseline, periodically during study treatment, and after completion of radical treatment.&#xD;
&#xD;
      After completion of radical treatment, patients are followed every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not meeting accrual target.&#xD;
  </why_stopped>
  <start_date type="Actual">June 15, 2007</start_date>
  <completion_date type="Actual">January 10, 2013</completion_date>
  <primary_completion_date type="Actual">December 31, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific Survival</measure>
    <time_frame>5 years 6 months</time_frame>
    <description>Time from the date of randomization to the date of death due to prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years 6 months</time_frame>
    <description>Time from randomization to the date of death due to any causes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Active Surveillance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radical Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical prostatectomy or radiotherapy based on patient and physician preference</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Radical prostatectomy</description>
    <arm_group_label>Radical Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>high dose rate temporary seed implant; permanent seed implant.</description>
    <arm_group_label>Radical Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external beam radiation therapy</intervention_name>
    <description>3D conformal radiation therapy; intensity modulated radiation therapy.</description>
    <arm_group_label>Radical Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsies</intervention_name>
    <description>Periodic repeat biopsies</description>
    <arm_group_label>Radical Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Diagnosed within 6 months prior to randomization&#xD;
&#xD;
          -  Patient has been classified as favorable risk as defined by the following:&#xD;
&#xD;
               -  Clinical stage T1b, T1c, T2a, or T2b at the time of diagnosis&#xD;
&#xD;
               -  Clinical (diagnostic biopsy) Gleason score ≤ 6&#xD;
&#xD;
               -  PSA ≤ 10.0 ng/mL&#xD;
&#xD;
          -  Physical examination, rectal examination, and transrectal ultrasound have been done&#xD;
             within 6 months prior to randomization and radiographic studies, if indicated, are&#xD;
             negative for metastasis&#xD;
&#xD;
          -  Patient is a suitable candidate for radical prostatectomy or radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0, 1, or 2&#xD;
&#xD;
          -  Patient has a minimum life expectancy of &gt; 10 years&#xD;
&#xD;
          -  In centers participating in the quality of life component of the study, the patient is&#xD;
             able (i.e., sufficiently fluent) and willing to complete the quality of life&#xD;
             questionnaires in either English or French&#xD;
&#xD;
          -  No history of other malignancies, except adequately treated non-melanoma skin cancer,&#xD;
             adequately treated superficial bladder cancer, or other solid tumors curatively&#xD;
             treated with no evidence of disease for ≥ 5 years from study randomization&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No previous treatment for prostate cancer, including surgery (excluding biopsy and&#xD;
             TURP), radiotherapy, or androgen deprivation therapy for greater than 3 months&#xD;
&#xD;
          -  No planned androgen therapy except in the context of radical therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence H. Klotz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam S. Kibel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University Siteman Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin G. Sanda, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian M. Thompson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Choo, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Parker, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden Hospital, Sulton, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Unit at Vancouver Coastal</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <results_first_submitted>March 30, 2017</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Surveillance</title>
          <description>Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression</description>
        </group>
        <group group_id="P2">
          <title>Radical Intervention</title>
          <description>Radical prostatectomy or radiotherapy based on patient and physician preference&#xD;
conventional surgery: Radical prostatectomy&#xD;
brachytherapy: high dose rate temporary seed implant; permanent seed implant.&#xD;
external beam radiation therapy: 3D conformal radiation therapy; intensity modulated radiation therapy.&#xD;
Biopsies: Periodic repeat biopsies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Surveillance</title>
          <description>Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression</description>
        </group>
        <group group_id="B2">
          <title>Radical Intervention</title>
          <description>Radical prostatectomy or radiotherapy based on patient and physician preference&#xD;
conventional surgery: Radical prostatectomy&#xD;
brachytherapy: high dose rate temporary seed implant; permanent seed implant.&#xD;
external beam radiation therapy: 3D conformal radiation therapy; intensity modulated radiation therapy.&#xD;
Biopsies: Periodic repeat biopsies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>age group : 40-49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age group : 50-59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age group : 60-69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age group : &gt;= 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age group : Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Stage*</title>
          <description>*According to the 6th Edition of the TNM Classification of Malignant Tumours. T1b Tumour incidental histological finding in more than 5% of tissue resected; T1c Tumour identified by needle biopsy, e.g., because of elevated prostate-specific antigen (PSA); T2a Tumour involves one-half of one lobe or less. T2b Tumour involves more than one-half of one lobe, but not both lobes.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T1B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status*</title>
          <description>*ECOG PERFORMANCE STATUS 0 : Fully active, able to carry on all pre-disease performance without restriction&#xD;
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work&#xD;
Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours&#xD;
Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours&#xD;
Completely disabled; cannot carry on any selfcare; totally confined to bed or chair&#xD;
Dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA value</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 5. ug/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 5. ug/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score (Combined)*</title>
          <description>*Gleason score: A grading system for prostate carcinoma devised by Dr. Donald Gleason in 1977 as a method for predicting the behavior of prostate cance.&#xD;
≤ 6: cancer cells that look similar to normal cells and suggest cancer grow slowly.&#xD;
7: intermediate risk for aggressive cancer. 8 - 10: cancers spread more rapidly, these cancers are often referred to as poorly differentiated or high grade.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-specific Survival</title>
        <description>Time from the date of randomization to the date of death due to prostate cancer.</description>
        <time_frame>5 years 6 months</time_frame>
        <population>Due to difficulty in accruing patients to the trial, the trial was closed early, there is no patient died of prostate cancer. Thus, no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Radical Intervention</title>
            <description>Radical prostatectomy or radiotherapy based on patient and physician preference&#xD;
conventional surgery: Radical prostatectomy&#xD;
brachytherapy: high dose rate temporary seed implant; permanent seed implant.&#xD;
external beam radiation therapy: 3D conformal radiation therapy; intensity modulated radiation therapy.&#xD;
Biopsies: Periodic repeat biopsies</description>
          </group>
          <group group_id="O2">
            <title>Active Surveillance</title>
            <description>Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-specific Survival</title>
          <description>Time from the date of randomization to the date of death due to prostate cancer.</description>
          <population>Due to difficulty in accruing patients to the trial, the trial was closed early, there is no patient died of prostate cancer. Thus, no analysis was done.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">There is no patient died of prostate cancer reported in the trial, so none of the reported value is available.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">There is no patient died of prostate cancer reported in the trial, so none of the reported value is available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time from randomization to the date of death due to any causes.</description>
        <time_frame>5 years 6 months</time_frame>
        <population>Due to lower patients accrual rate, the trial was closed early with only 3 events reported in the trial, Thus.no formal analysis had been done.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance</title>
            <description>Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression</description>
          </group>
          <group group_id="O2">
            <title>Radical Intervention</title>
            <description>Radical prostatectomy or radiotherapy based on patient and physician preference&#xD;
conventional surgery: Radical prostatectomy&#xD;
brachytherapy: high dose rate temporary seed implant; permanent seed implant.&#xD;
external beam radiation therapy: 3D conformal radiation therapy; intensity modulated radiation therapy.&#xD;
Biopsies: Periodic repeat biopsies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from randomization to the date of death due to any causes.</description>
          <population>Due to lower patients accrual rate, the trial was closed early with only 3 events reported in the trial, Thus.no formal analysis had been done.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">There is no patient died of prostate cancer reported in the trial, so none of the reported value is available.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">There is no patient died of prostate cancer reported in the trial, so none of the reported value is available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>q 3 months for 2 years then every 6 months for 5 years and 6 months.</time_frame>
      <desc>Adverse events graded according to CTCAE V4.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Surveillance</title>
          <description>Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression</description>
        </group>
        <group group_id="E2">
          <title>Radical Intervention</title>
          <description>Radical prostatectomy or radiotherapy based on patient and physician preference&#xD;
conventional surgery: Radical prostatectomy&#xD;
brachytherapy: high dose rate temporary seed implant; permanent seed implant.&#xD;
external beam radiation therapy: 3D conformal radiation therapy; intensity modulated radiation therapy.&#xD;
Biopsies: Periodic repeat biopsies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE V4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pain Testicle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="78"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculatory dysfunction</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="78"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the early termination of the trial, the small number of patients and the shorter follow up, the reported information may not be reliable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Keyue Ding, Biostatistician</name_or_title>
      <organization>Canadian Cancer Trials Group</organization>
      <phone>613-533-6430</phone>
      <email>kding@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

